Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC12690MLN8237 (Alisertib)CAS: 1028486-01-2纯度: >99.00%
Alisertib (MLN8237) 作为一种在研、可口服的选择性极光 A 激酶抑制剂,通常用于治疗实体瘤和血液系统恶性肿瘤。
- GC12756MK-4827 hydrochlorideCAS: 1038915-64-8纯度: >99.50%
MK-4827 hydrochloride (MK-4827 hydrochloride) 是一种高效且具有口服生物利用度的 PARP1 和 PARP2 抑制剂,IC50 分别为 3.8 和 2.1 nM。 MK-4827 hydrochloride 抑制 DNA 损伤的修复,激活细胞凋亡并显示出抗肿瘤活性。
- GC12793RITA (NSC 652287)CAS: 213261-59-7纯度: >99.00%
RITA (NSC 652287)是一种三环噻吩衍生物,可结合p53dN(K d =1.5nM)并阻断p53-HDM-2相互作用,抑制p53泛素化。
- GC12942DAPT (GSI-IX)CAS: 208255-80-5纯度: >98.00%
DAPT (GSI-IX) 是一种具有口服活性的 γ-分泌酶抑制剂,对人原代神经元培养物中产生的总淀粉样蛋白-β (Aβ) 和 Aβ42 的 IC50 分别为 115 nM 和 200 nM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC12604 | Fumonisin B1 | 116355-83-0 | >98.00% / >95.00% | |
A mycotoxin | ||||
| GC12612 | JNJ-7706621 | 443797-96-4 | >99.50% | |
A dual inhibitor of CDKs and Aurora kinases | ||||
| GC12621 | S63845 | 1799633-27-4 | >99.00% / >98.00% | |
S63845是一种有效的选择性骨髓细胞白血病1(MCL1)抑制剂,K d 值为0.19nM(人MCL1)。 | ||||
| GC12639 | NS3694 | 426834-38-0 | - | |
An inhibitor of apoptosome formation and caspase activation | ||||
| GC12660 | AZD1208 | 1204144-28-4 | >98.00% | |
AZD1208 是一种有效、高选择性且可口服的 Pim 激酶抑制剂,对 PIM1、PIM2 和 PIM3 的 IC50 值分别为 0.4、5 和 1.9nM。 | ||||
| GC12690 | MLN8237 (Alisertib) | 1028486-01-2 | >99.00% | |
Alisertib (MLN8237) 作为一种在研、可口服的选择性极光 A 激酶抑制剂,通常用于治疗实体瘤和血液系统恶性肿瘤。 | ||||
| GC12709 | XL147 | 956958-53-5 | >99.50% | |
An analog of XL147 | ||||
| GC12718 | Pantoprazole | 102625-70-7 | - | |
A proton pump inhibitor | ||||
| GC12733 | C646 | 328968-36-1 | >98.00% | |
C646是一种有效的选择性p300/CBP组蛋白乙酰转移酶抑制剂(Ki 400 nM),已被证明具有多效性,包括神经保护、抗癌和抗上皮间质转化(anti-EMT)作用。 | ||||
| GC12756 | MK-4827 hydrochloride | 1038915-64-8 | >99.50% | |
MK-4827 hydrochloride (MK-4827 hydrochloride) 是一种高效且具有口服生物利用度的 PARP1 和 PARP2 抑制剂,IC50 分别为 3.8 和 2.1 nM。 MK-4827 hydrochloride 抑制 DNA 损伤的修复,激活细胞凋亡并显示出抗肿瘤活性。 | ||||
| GC12773 | Palomid 529 | 914913-88-5 | >99.00% | |
An inhibitor of mTORC1 and mTORC2 formation | ||||
| GC12793 | RITA (NSC 652287) | 213261-59-7 | >99.00% | |
RITA (NSC 652287)是一种三环噻吩衍生物,可结合p53dN(K d =1.5nM)并阻断p53-HDM-2相互作用,抑制p53泛素化。 | ||||
| GC12801 | Rasagiline Mesylate | 161735-79-1 | >99.50% | |
An inhibitor of MAO-B | ||||
| GC12821 | Oltipraz | 64224-21-1 | >99.50% | |
A Nrf2 and CAR activator | ||||
| GC12822 | BML-210(CAY10433) | 537034-17-6 | - | |
A potent, synthetic HDAC inhibitor | ||||
| GC12830 | Stavudine (d4T) | 3056-17-5 | >99.50% | |
An inhibitor of HIV reverse transcriptase | ||||
| GC12838 | Edaravone | 89-25-8 | >99.50% | |
Edaravone是一种经典的自由基清除剂,作为有机小分子可穿越血脑屏障,为脑细胞提供保护。 | ||||
| GC12857 | R1530 | 882531-87-5 | >99.00% | |
A multi-kinase inhibitor | ||||
| GC12891 | CCT007093 | 176957-55-4 | >98.00% | |
An inhibitor of PPM1D | ||||
| GC12902 | Pyridoclax | 1651890-44-6 | >99.50% | |
Pyridoclax 是一种潜在的 Mcl-1 抑制剂。 | ||||
| GC12919 | Pralatrexate | 146464-95-1 | >98.00% | |
A dihydrofolate reductase inhibitor | ||||
| GC12940 | Fidaxomicin | 873857-62-6 | >99.50% | |
A natural antibiotic | ||||
| GC12942 | DAPT (GSI-IX) | 208255-80-5 | >98.00% | |
DAPT (GSI-IX) 是一种具有口服活性的 γ-分泌酶抑制剂,对人原代神经元培养物中产生的总淀粉样蛋白-β (Aβ) 和 Aβ42 的 IC50 分别为 115 nM 和 200 nM。 | ||||
| GC12961 | Apicidin | 183506-66-3 | >98.00% / >90.00% | |
A cell-permeable HDAC inhibitor | ||||
